Badrul A.  Chowdhury net worth and biography

Badrul Chowdhury Biography and Net Worth

Insider of Savara
Dr. Chowdhury joined Savara as Chief Medical Officer in November 2019. Previously he was at AstraZeneca where he held the position of Senior Vice President, Chief Physician-Scientist for Respiratory Inflammation and Autoimmunity Late Stage Development in Biopharmaceuticals. For 16 years prior to that, Dr. Chowdhury served as Director, Division of Pulmonary, Allergy, and Rheumatology Products, Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) where he provided scientific and regulatory oversight of both common and rare diseases such as asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, rheumatoid arthritis, systemic lupus erythromatosis, and various autoimmune and inflammatory diseases. Dr. Chowdhury is a medical doctor, and also holds a Ph.D. in Immunology. He completed Internal Medicine Residency training from the Wayne State University School of Medicine, Detroit, Michigan, and Fellowship training in Allergy and Immunology from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, Maryland. He is double board certified in Internal Medicine and Allergy and Immunology.

What is Badrul A. Chowdhury's net worth?

The estimated net worth of Badrul A. Chowdhury is at least $604,000.00 as of May 17th, 2021. Dr. Chowdhury owns 200,000 shares of Savara stock worth more than $604,000 as of December 18th. This net worth approximation does not reflect any other investments that Dr. Chowdhury may own. Learn More about Badrul A. Chowdhury's net worth.

How do I contact Badrul A. Chowdhury?

The corporate mailing address for Dr. Chowdhury and other Savara executives is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. Savara can also be reached via phone at 512-614-1848 and via email at [email protected]. Learn More on Badrul A. Chowdhury's contact information.

Has Badrul A. Chowdhury been buying or selling shares of Savara?

Badrul A. Chowdhury has not been actively trading shares of Savara during the past quarter. Most recently, on Thursday, December 9th, Badrul A. Chowdhury bought 25,000 shares of Savara stock. The stock was acquired at an average cost of $1.05 per share, with a total value of $26,250.00. Learn More on Badrul A. Chowdhury's trading history.

Who are Savara's active insiders?

Savara's insider roster includes Badrul Chowdhury (Insider), Matthew Pauls (CEO), and David Ramsay (Director). Learn More on Savara's active insiders.

Are insiders buying or selling shares of Savara?

In the last twelve months, Savara insiders bought shares 1 times. They purchased a total of 20,000 shares worth more than $59,000.00. In the last twelve months, insiders at the sold shares 4 times. They sold a total of 242,545 shares worth more than $1,065,804.15. The most recent insider tranaction occured on December, 16th when CEO Matthew Pauls sold 54,702 shares worth more than $181,063.62. Insiders at Savara own 5.1% of the company. Learn More about insider trades at Savara.

Information on this page was last updated on 12/16/2024.

Badrul A. Chowdhury Insider Trading History at Savara

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/9/2021Buy25,000$1.05$26,250.00View SEC Filing Icon  
5/17/2021Sell50,000$1.56$78,000.00200,000View SEC Filing Icon  
See Full Table

Badrul A. Chowdhury Buying and Selling Activity at Savara

This chart shows Badrul A Chowdhury's buying and selling at Savara by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Savara Company Overview

Savara logo
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Read More

Today's Range

Now: $3.02
Low: $2.99
High: $3.25

50 Day Range

MA: $3.50
Low: $2.94
High: $4.07

2 Week Range

Now: $3.02
Low: $2.82
High: $5.70

Volume

690,244 shs

Average Volume

1,271,406 shs

Market Capitalization

$518.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92